Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496402 | 0.84 | FGFR1 (0.54) | ALDH1A1MAPTFGFR1GRM5KMT2A | |
| SCHEMBL13136881 | 0.81 | DYRK1A (0.57) | DYRK1APRKCIFGFR1 | |
| SCHEMBL16478979 | 0.78 | DYRK1A (0.50) | DYRK1AALDH1A1MAPTPRKCINOTUM | |
| SCHEMBL4821253 | 0.78 | DYRK1A (0.53) | DYRK1AALDH1A1MAPTPRKCINOTUM | |
| SCHEMBL30263530 | 0.78 | DYRK1A (0.53) | DYRK1AALDH1A1MAPTPRKCINOTUM | |
| SCHEMBL29522878 | 0.78 | DYRK1A (0.53) | DYRK1AALDH1A1MAPTPRKCIFGFR1 | |
| SCHEMBL2739230 | 0.78 | DYRK1A (0.53) | DYRK1AALDH1A1MAPTPRKCIFGFR1 | |
| SCHEMBL2144640 | 0.76 | DYRK1A (0.51) | DYRK1AALDH1A1MAPTPRKCINOTUM | |
| SCHEMBL745777 | 0.76 | DYRK1A (0.51) | DYRK1AALDH1A1MAPTPRKCIFGFR1 | |
| SCHEMBL14855712 | 0.76 | DYRK1A (0.51) | DYRK1AALDH1A1MAPTPRKCINOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630536-B2 | Cyanotriazine derivative, preparation method therefor, and application thereof | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2024215809-A2 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230312527-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20140221345-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014100730-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2084162-B1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011032050-A2 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| EP-2084162-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630536-B2 | Cyanotriazine derivative, preparation method therefor, and application thereof | THRB, SLC10A1, THRA | DYRK1A 2596/4885ALDH1A1 1905/4885MAPT 2523/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | DYRK1A 1325/4885ALDH1A1 1816/4885MAPT 4652/4885 |
| US-20140221345-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DYRK1A 2725/4885ALDH1A1 2460/4885MAPT 2923/4885 |
| US-20230312527-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | THRB, SLC5A1, SLC10A1 | DYRK1A 2896/4885ALDH1A1 2753/4885MAPT 3839/4885 |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | DYRK1A 1599/4885ALDH1A1 2577/4885MAPT 1208/4885 |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | DYRK1A 4607/4885ALDH1A1 1769/4885MAPT 4715/4885 |
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | DYRK1A 24/4885ALDH1A1 4593/4885MAPT 72/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | DYRK1A 3409/4885ALDH1A1 1957/4885MAPT 3664/4885 |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | MAP3K20, TTK, PRKACB | DYRK1A 472/4885ALDH1A1 4730/4885MAPT 1886/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | DYRK1A 2488/4885ALDH1A1 2681/4885MAPT 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.